Search Results - "Goodin, S."

The nature of genetic and environmental susceptibility to multiple sclerosis by Goodin, Douglas S, Khankhanian, Pouya, Gourraud, Pierre-Antoine, Vince, Nicolas

“…To understand the nature of genetic and environmental susceptibility to multiple sclerosis (MS) and, by extension, susceptibility to other complex genetic…”
Get full text

Silent progression in disease activity–free relapsing multiple sclerosis by Cree, Bruce A. C., Hollenbach, Jill A., Bove, Riley, Kirkish, Gina, Sacco, Simone, Caverzasi, Eduardo, Bischof, Antje, Gundel, Tristan, Zhu, Alyssa H., Papinutto, Nico, Stern, William A., Bevan, Carolyn, Romeo, Andrew, Goodin, Douglas S., Gelfand, Jeffrey M., Graves, Jennifer, Green, Ari J., Wilson, Michael R., Zamvil, Scott S., Zhao, Chao, Gomez, Refujia, Ragan, Nicholas R., Rush, Gillian Q., Barba, Patrick, Santaniello, Adam, Baranzini, Sergio E., Oksenberg, Jorge R., Henry, Roland G., Hauser, Stephen L.

“…Objective Rates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in actively treated patients compared to…”
Get full text

Multiple sclerosis: Exploring the limits and implications of genetic and environmental susceptibility by Goodin, Douglas S, Khankhanian, Pouya, Gourraud, Pierre-Antoine, Vince, Nicolas

“…To explore and describe the basis and implications of genetic and environmental susceptibility to multiple sclerosis (MS) using the Canadian population-based…”
Get full text

The causal cascade to multiple sclerosis: a model for MS pathogenesis by Goodin, Douglas S

“…MS pathogenesis seems to involve both genetic susceptibility and environmental risk factors. Three sequential factors are implicated in the environmental risk…”
Get full text

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases by Medina, Patrick J., PharmD, BCOP, Goodin, Susan, PharmD, FCCP, BCOP

“…Abstract Background: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)…”
Get full text

Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility by Goodin, Douglas S, Khankhanian, Pouya, Gourraud, Pierre-Antoine, Vince, Nicolas

“…To determine the relationship between highly-conserved extended-haplotypes (CEHs) in the major histocompatibility complex (MHC) and MS-susceptibility. Among…”
Get full text

Incidental MRI anomalies suggestive of multiple sclerosis : The radiologically isolated syndrome by OKUDA, D. T, MOWRY, E. M, BEHESHTIAN, A, WAUBANT, E, BARANZINI, S. E, GOODIN, D. S, HAUSER, S. L, PELLETIER, D

“…The discovery and broad application of MRI in medicine has led to an increased awareness in the number of patients with incidental white matter pathology in…”
Get full text

Genetic susceptibility to multiple sclerosis in African Americans by Goodin, Douglas S, Oksenberg, Jorge R, Douillard, Venceslas, Gourraud, Pierre-Antoine, Vince, Nicolas

“…Objective To explore the nature of genetic-susceptibility to multiple sclerosis (MS) in African-Americans. Background Recently, the number of…”
Get full text

Disease-modifying therapy in multiple sclerosis: update and clinical implications by Goodin, Douglas S

“…As new therapies become available for the treatment of multiple sclerosis, the relative value of established and newer disease-modifying therapies must be…”
Get full text

Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial by GOODIN, D. S, REDER, A. T, KNAPPERTZ, V, EBERS, G. C, CUTTER, G, KREMENCHUTZKY, M, OGER, J, LANGDON, D, RAMETTA, M, BECKMANN, K, DESIMONE, T. M

“…To examine the effects of interferon beta (IFNβ)-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the pivotal…”
Get full text

Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions by Goodin, D S, Khankhanian, P, Gourraud, P A, Vince, N

“…To study the accumulation of MS-risk resulting from different combinations of MS-associated conserved-extended-haplotypes (CEHs) of the MHC and three non-MHC…”
Get full text

Feasibility of an implantable bioreactor for renal cell therapy using silicon nanopore membranes by Kim, Eun Jung, Chen, Caressa, Gologorsky, Rebecca, Santandreu, Ana, Torres, Alonso, Wright, Nathan, Goodin, Mark S., Moyer, Jarrett, Chui, Benjamin W., Blaha, Charles, Brakeman, Paul, Vartanian, Shant, Tang, Qizhi, David Humes, H., Fissell, William H., Roy, Shuvo

“…The definitive treatment for end-stage renal disease is kidney transplantation, which remains limited by organ availability and post-transplant complications…”
Get full text

Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes by Gelfand, Jeffrey M, Goodin, Douglas S, Boscardin, W John, Nolan, Rachel, Cuneo, Ami, Green, Ari J

“…To determine whether retinal axonal loss is detectable in patients with a clinically isolated syndrome (CIS), a first clinical demyelinating attack suggestive…”
Get full text

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial by Ebers, G C, Traboulsee, A, Li, D, Langdon, D, Reder, A T, Goodin, D S, Bogumil, T, Beckmann, K, Wolf, C, Konieczny, A

“…BackgroundEvidence for efficacy of disease-modifying drugs in multiple sclerosis (MS) comes from trials of short duration. We report results from a 16 y,…”
Get full text

Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome by OKUDA, D. T, MOWRY, E. M, CREE, B. A. C, CRABTREE, E. C, GOODIN, D. S, WAUBANT, E, PELLETIER, D

“…Technological advancements in neuroimaging and the increased use of these diagnostic modalities are responsible for the discovery of incidentally identified…”
Get full text

Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis by Schlaeger, Regina, Papinutto, Nico, Zhu, Alyssa H, Lobach, Iryna V, Bevan, Carolyn J, Bucci, Monica, Castellano, Antonella, Gelfand, Jeffrey M, Graves, Jennifer S, Green, Ari J, Jordan, Kesshi M, Keshavan, Anisha, Panara, Valentina, Stern, William A, von Büdingen, H-Christian, Waubant, Emmanuelle, Goodin, Douglas S, Cree, Bruce A C, Hauser, Stephen L, Henry, Roland G

“…In multiple sclerosis (MS), upper cervical cord gray matter (GM) atrophy correlates more strongly with disability than does brain or cord white matter (WM)…”
Get more information

Single nucleotide polymorphism (SNP)-strings: an alternative method for assessing genetic associations by Goodin, Douglas S, Khankhanian, Pouya

“…Genome-wide association studies (GWAS) identify disease-associations for single-nucleotide-polymorphisms (SNPs) from scattered genomic-locations. However, SNPs…”
Get full text

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode by GOODIN, D. S, BATES, D

“…Multiple sclerosis is a chronic, demyelinating disorder of the central nervous system. It is characterised by progressive neurological disability, which is…”
Get full text

Evidence-based guideline update: Intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society by NUWER, M. R, EMERSON, R. G, GRONSETH, G. S, HARDEN, C. L, GALLOWAY, G, LEGATT, A. D, LOPEZ, J, MINAHAN, R, YAMADA, T, GOODIN, D. S, ARMON, C, CHAUDHRY, V

“…To evaluate whether spinal cord intraoperative monitoring (IOM) with somatosensory and transcranial electrical motor evoked potentials (EPs) predicts adverse…”
Get full text

Causes of death among commercially insured multiple sclerosis patients in the United States by Goodin, Douglas S, Corwin, Michael, Kaufman, David, Golub, Howard, Reshef, Shoshana, Rametta, Mark J, Knappertz, Volker, Cutter, Gary, Pleimes, Dirk

“…Information on causes of death (CODs) for patients with multiple sclerosis (MS) in the United States is sparse and limited by standard categorizations of…”
Get full text